Cantor Fitzgerald Upgrades Korro Bio on Promise of KRRO-121
Cantor Fitzgerald upgrades Korro Bio to Overweight, citing strong preclinical data and market potential for its lead program KRRO-121.
/ 2 items
Cantor Fitzgerald upgrades Korro Bio to Overweight, citing strong preclinical data and market potential for its lead program KRRO-121.
Korro Bio is focusing on new genetic medicines (GalNAc programs) after poor trial results for KRRO-110, pausing its Novo Nordisk partnership, and reducing its staff by 34%.